Azitra (NYSEAMERICAN:AZTR – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.05), FiscalAI reports.
Azitra Stock Performance
Shares of Azitra stock opened at $0.14 on Friday. Azitra has a 12-month low of $0.10 and a 12-month high of $1.40. The firm’s 50 day simple moving average is $0.16 and its two-hundred day simple moving average is $0.19.
About Azitra
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Featured Stories
- Five stocks we like better than Azitra
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
